Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NEOGENOMICS INC Director's Dealing 2021

Jul 8, 2021

32227_dirs_2021-07-07_1b0dcff6-e0bf-4bbf-8163-8db5f3bbbff6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2021-07-05

Reporting Person: Wallar Gina M (President, Pharma Services)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 4117 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $9.22 2023-04-19 Common Stock (6667.0) Direct
Stock Option (Right to Buy) $13.87 2023-12-12 Common Stock (8334.0) Direct
Stock Option (Right to Buy) $20.83 2026-05-01 Common Stock (7153.0) Direct
Stock Option (Right to Buy) $27.34 2027-05-01 Common Stock (7879.0) Direct
Stock Option (Right to Buy) $48.99 2028-05-01 Common Stock (8595.0) Direct

Footnotes

F1: On April 19, 2018, Ms. Wallar was granted 20,000 stock options. The options vested ratably over the first three anniversary dates of the grant date.

F2: On December 12, 2018, Ms. Wallar was granted 25,000 stock options. The options vest ratably over the first three anniversary dates of the grant date.

F3: On May 1, 2019, Ms. Wallar was granted 9,537 stock options. The options vest ratably over the first four anniversary dates of the grant date.

F4: On May 1, 2020, Ms. Wallar was granted 7,879 stock options. The options vest ratably over the first four anniversary dates of the grant date.

F5: On May 1, 2021, Ms. Wallar was granted 8,595 stock options. The options vest ratably over the first four anniversary dates of the grant date.